Lymphoma
2026-05-22
EORTC Cutaneous Lymphoma RT Recommendations
ForPrimary cutaneous lymphoma (all subtypes), any stage requiring RT
EORTC expert consensus on low-dose RT for all primary cutaneous lymphoma subtypes; no controlled trial data; retrospective evidence only.
6 details
- 🔍 Expert opinion + systematic literature review; not a clinical trial; no randomized dose-comparison data for any cutaneous lymphoma entity
- 🔍 Covers all primary cutaneous lymphoma subtypes: T-cell (MF, Sézary syndrome) and B-cell (PCMZL, PCFCL, PCDLBCL leg-type)
- 💊 Low-dose RT increasingly adopted; rationale: high radiosensitivity of cutaneous lymphoma lesions, low toxicity profile, retreatment feasibility
- 📊 No effect sizes reported in source; evidence base limited to retrospective case series + limited prospective TSEBT registry data in advanced-stage MF
- ⚠️ No controlled trials defining standard dose for any specific entity; recommendations are consensus-driven, not trial-validated
- ⚠️ Multi-institution, multi-national authorship (EORTC CLTG) lends credibility but cannot substitute for prospective randomized evidence
📚 Sources · 📄 1 paper
Radiotherapy in cutaneous lymphomas: Recommendations from the EORTC cutaneous lymphoma tumour group
Abstract
The number of primary cutaneous lymphoma patients receiving low-dose radiotherapy is increasing, though controlled clinical trials defining the standard radiation dose for each specific entity have not yet been completed. Radiation oncologists are left with making highly individualized decisions that would be better enriched by additional clinical evidence. In this expert opinion, we aim to provide a clear recommendation to improve the current practice of radiation oncology. In addition, existing literature has been reviewed to develop recommendations for all types of primary cutaneous lymphoma. A prospective trial is urgently needed to identify the factors influencing patient outcomes following different radiation doses.